Education
About Us
Working with TipRanks
Follow Us
Anebulo Pharmaceuticals, Inc. (ANEB)
:ANEB
ANEB Stock Chart & Stats
Day’s Range― - ―
52-Week Range$0.80 - $3.42
Previous CloseN/A
Volume2.65K
Average Volume (3M)779.36K
Market Cap
$110.93M
Enterprise Value$40.13M
Total Cash (Recent Filing)$13.28M
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta0.84
Next Earnings
Sep 17, 2025EPS Estimate
-0.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-0.04
Shares Outstanding41,084,732
10 Day Avg. Volume279,773
30 Day Avg. Volume779,359
Financial Highlights & Ratios
PEG RatioN/A
Price to Book (P/B)0.00
Price to Sales (P/S)0.00
P/FCF Ratio0.00
Enterprise Value/Market Cap0.36
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/Ebitda-5.52
Forecast
1Y Price Target
$3.00Price Target Upside11.11% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering2
Bulls Say, Bears Say
Bulls Say
Corporate StrategyBoard approves plan to go private at a 91% premium to previous close.
Financial StabilityAnebulo Pharmaceuticals has adequate financial resources to fund operations well into calendar year 2026.
Regulatory SupportThe company received positive reinforcement from the US FDA related to an unmet need for a treatment for children exposed to cannabis toxicity.
Bears Say
Market ValuationThe analyst downgraded shares to Hold from Buy due to limited upside potential as the stock price approached the transaction price.
Price TargetThe upside potential is limited as the shares approach the transaction price and exceed the 12-month price target.
Stock RatingStock rating downgraded to Hold.
Anebulo Pharmaceuticals News
ANEB FAQ
What was Anebulo Pharmaceuticals, Inc.’s price range in the past 12 months?
Anebulo Pharmaceuticals, Inc. lowest stock price was $0.80 and its highest was $3.42 in the past 12 months.
What is Anebulo Pharmaceuticals, Inc.’s market cap?
Anebulo Pharmaceuticals, Inc.’s market cap is $110.93M.
When is Anebulo Pharmaceuticals, Inc.’s upcoming earnings report date?
Anebulo Pharmaceuticals, Inc.’s upcoming earnings report date is Sep 17, 2025 which is in 40 days.
How were Anebulo Pharmaceuticals, Inc.’s earnings last quarter?
Anebulo Pharmaceuticals, Inc. released its earnings results on May 13, 2025. The company reported -$0.04 earnings per share for the quarter, beating the consensus estimate of -$0.05 by $0.01.
Is Anebulo Pharmaceuticals, Inc. overvalued?
According to Wall Street analysts Anebulo Pharmaceuticals, Inc.’s price is currently Undervalued.
Does Anebulo Pharmaceuticals, Inc. pay dividends?
Anebulo Pharmaceuticals, Inc. does not currently pay dividends.
What is Anebulo Pharmaceuticals, Inc.’s EPS estimate?
Anebulo Pharmaceuticals, Inc.’s EPS estimate is -0.07.
How many shares outstanding does Anebulo Pharmaceuticals, Inc. have?
Anebulo Pharmaceuticals, Inc. has 41,084,732 shares outstanding.
What happened to Anebulo Pharmaceuticals, Inc.’s price movement after its last earnings report?
Anebulo Pharmaceuticals, Inc. reported an EPS of -$0.04 in its last earnings report, beating expectations of -$0.05. Following the earnings report the stock price went same 0%.
Which hedge fund is a major shareholder of Anebulo Pharmaceuticals, Inc.?
Currently, no hedge funds are holding shares in ANEB
Anebulo Pharmaceuticals Stock Smart Score
Underperform
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$3.00 (11.11% Upside)
$3.00 (11.11% Upside)
News Sentiment
Neutral
Bullish news 59%
Bearish news 50%
Bearish news 50%
Technicals
SMA
Positive
20 days / 200 days
Momentum
21.21%
12-Months-Change
Fundamentals
Return on Equity
-83.37%
Trailing 12-Months
Asset Growth
133.64%
Trailing 12-Months
Company Description
Anebulo Pharmaceuticals, Inc.
Anebulo Pharmaceuticals (ANEB) is a clinical-stage biotechnology company focused on developing novel treatments for patients suffering from cannabinoid overdose and substance addiction. The company primarily operates within the pharmaceutical and biotechnology sectors, targeting unmet medical needs related to the growing marijuana and cannabinoid markets. Anebulo's lead product candidate, ANEB-001, is an orally administered small molecule designed to treat acute cannabinoid intoxication.
ANEB Stock 12 Month Forecast
Average Price Target
$3.00
▲(11.11% Upside)
Technical Analysis
Actinium Pharmaceuticals
―
vTv Therapeutics
―
Prelude Therapeutics
―
Aligos Therapeutics
―
Hyperfine
―
Ownership Overview
78.18% Insiders
0.58% Mutual Funds
0.85% Other Institutional Investors
20.00% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---